Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Janet Woodcock’s post-FDA plans are starting to take shape and include a new advisory role at the Haystack Project, a rare disease nonprofit.
The decision to join the organization, a coalition of ultra rare and rare disease patient groups, is indicative of